Dec 27, 2024

Public workspaceBibliometric and Visual Analysis of Fibrotic Pulmonary Sarcoidosis

DOI
dx.doi.org/10.17504/protocols.io.3byl4w312vo5/v1
  • Namin Wei1,
  • Huyen Thi Thanh Nguyen2,
  • Xinhua Fang3,
  • Xuelong Zhao4,
  • Fengping Zeng1,
  • Chenqian Yu1,
  • Fanlin Yang1,
  • Feiyu Li1,
  • Huanfei Yang1,
  • Hongmei Chen3,
  • Huaqiang Zhai1
  • 1Standardization Research Center of Traditional Chinese Medicine Dispensing, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 102488, China.;
  • 2International School of Beijing University of Chinese Medicine, Beijing, 102488, China.;
  • 3Department of Pharmacy, Hangzhou Traditional Chinese Medicine Hospital, Hangzhou, 311121, China.;
  • 4Department of Pharmacy, Nanjing Traditional Chinese Medicine Hospital, Nanjing, 210022, China.
Huyen Thi Thanh Nguyen
Icon indicating open access to content
QR code linking to this content
DOI: dx.doi.org/10.17504/protocols.io.3byl4w312vo5/v1
Protocol Citation: Namin Wei, Huyen Thi Thanh Nguyen, Xinhua Fang, Xuelong Zhao, Fengping Zeng, Chenqian Yu, Fanlin Yang, Feiyu Li, Huanfei Yang, Hongmei Chen, Huaqiang Zhai 2024. Bibliometric and Visual Analysis of Fibrotic Pulmonary Sarcoidosis. protocols.io https://dx.doi.org/10.17504/protocols.io.3byl4w312vo5/v1
Manuscript citation:

License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License,  which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: December 26, 2024
Last Modified: December 27, 2024
Protocol Integer ID: 117289
Keywords: Fibrotic Pulmonary Sarcoidosis, CiteSpace, Bibliometrics, Visualization
Funders Acknowledgements:
National Natural Science Foundation of China (Beijing, China)
Grant ID: 82374055
Abstract
Fibrotic pulmonary sarcoidosis (FPS) has a high mortality rate, yet its pathogenesis remains unclear, and effective treatments are lacking. This study performs a bibliometric and visual analysis of the existing literature on FPS to address the gap in research trends and hotspots. A total of 962 relevant publications were analyzed using CiteSpace to explore publication years, scientific collaboration networks, journals, references, and keywords. The results show a steady increase in FPS research, with key authors and institutions driving research forward, and emerging hotspots covering related diseases, complications, treatments, and biomarkers. This study provides valuable insights into FPS research trends and future directions.
Attachments
Icon for Data
Data
Data collection
Data collection
The literature was retrieved from the Web of Science Core Collection SCI-Expanded on January 9, 2024, using the following search terms: - Search Terms: "fibrotic pulmonary sarcoidosis" OR "pulmonary fibrosis in sarcoidosis"
Time Frame: Unlimited
- Language: English
- Document Types: Article and review article
A total of 962 publications were retrieved, saved as plain text files with full records and cited references in the download_.txt format.
Data Analysis
Data Analysis
- CiteSpace 6.2.R6 (64-bit) Advanced was used to analyze all 962 records. The analysis involved constructing visual knowledge maps for: Co-author, Co-cited author, Co-country, Co-institution, Co-cited journal, Co-cited reference, Co-keyword.
- The parameters used for the analysis were: Time Slice: 2004-2024, Years per Slice: 2, Term Source: Entire selection, Node Type: One at a time, Selection Criteria: Top N=50.
Protocol references
1. E. Bargagli, A. Prasse, Sarcoidosis: a review for the internist, Intern Emerg Med 13(3) (2018) 325-331.
2. E.D. Crouser, L.A. Maier, K.C. Wilson, C.A. Bonham, A.S. Morgenthau, K.C. Patterson, E. Abston, R.C. Bernstein, R. Blankstein, E.S. Chen, D.A. Culver, W. Drake, M. Drent, A.K. Gerke, M. Ghobrial, P. Govender, N. Hamzeh, W.E. James, M.A. Judson, L. Kellermeyer, S. Knight, L.L. Koth, V. Poletti, S.V. Raman, M.H. Tukey, G.E. Westney, R.P. Baughman, Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline, Am J Respir Crit Care Med 201(8) (2020) e26-e51.
3. G. Rossi, A. Cavazza, T.V. Colby, Pathology of Sarcoidosis, Clin Rev Allergy Immunol 49(1) (2015) 36-44.
4. V. Kouranos, A. Wells, S. Walsh, Why do people die from pulmonary sarcoidosis?, Curr Opin Pulm Med 24(5) (2018) 527-535.
5. D. Cozzi, E. Bargagli, A.G. Calabrò, E. Torricelli, F. Giannelli, E. Cavigli, V. Miele, Atypical HRCT manifestations of pulmonary sarcoidosis, Radiol Med 123(3) (2018) 174-184.
6. I. Mochizuki, K. Kubo, T. Hond, Widespread heavy damage of capillary endothelial cells in the pathogenesis of sarcoidosis--Evidence by monoclonal von Willebrand factor immunohistochemistry in the bronchus and lung of patients with sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis 31(3) (2014) 182-90.
7. P. Weeratunga, D.R. Moller, L.P. Ho, Immune mechanisms in fibrotic pulmonary sarcoidosis, Eur Respir Rev 31(166) (2022).
8. E.V. Arkema, Y.C. Cozier, Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors, Curr Opin Pulm Med 26(5) (2020) 527-534.
9. A. Nardi, P.Y. Brillet, P. Letoumelin, F. Girard, M. Brauner, Y. Uzunhan, J.M. Naccache, D. Valeyre, H. Nunes, Stage IV sarcoidosis: comparison of survival with the general population and causes of death, Eur Respir J 38(6) (2011) 1368-73.
10. A. Sinha, K.K. Lee, G.F. Rafferty, N. Yousaf, I.D. Pavord, J. Galloway, S.S. Birring, Predictors of objective cough frequency in pulmonary sarcoidosis, Eur Respir J 47(5) (2016) 1461-71.
11. C.A. Bonham, M.E. Strek, K.C. Patterson, From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis, Curr Opin Pulm Med 22(5) (2016) 484-91.
12. M. d'Alessandro, L. Bergantini, A. Perrone, P. Cameli, M. Cameli, A. Prasse, D. Plataroti, P. Sestini, E. Bargagli, Serial investigation of Angiotensin-Converting Enzyme in sarcoidosis patients treated with Angiotensin-Converting Enzyme Inhibitor, Eur J Intern Med 78 (2020) 58-62.
13. M. Drent, E.D. Crouser, J. Grunewald, Challenges of Sarcoidosis and Its Management, N Engl J Med 385(11) (2021) 1018-1032.
14. F. Jeny, Y. Uzunhan, M. Lacroix, T. Gille, P.Y. Brillet, A. Nardi, D. Bouvry, C. Planès, H. Nunes, D. Valeyre, Predictors of mortality in fibrosing pulmonary sarcoidosis, Respir Med 169 (2020) 105997.
15. I.R. Konigsberg, L.A. Maier, I.V. Yang, Epigenetics and sarcoidosis, Eur Respir Rev 30(160) (2021).
16. H. Nunes, P.Y. Brillet, J.F. Bernaudin, T. Gille, D. Valeyre, F. Jeny, Fibrotic Pulmonary Sarcoidosis, Clin Chest Med 45(1) (2024) 199-212.
17. R. Gupta, R.P. Baughman, Advanced Pulmonary Sarcoidosis, Semin Respir Crit Care Med 41(5) (2020) 700-715.
18. R. Gupta, M.A. Judson, R.P. Baughman, Management of Advanced Pulmonary Sarcoidosis, Am J Respir Crit Care Med 205(5) (2022) 495-506.
19. R. Gupta, J.S. Kim, R.P. Baughman, An expert overview of pulmonary fibrosis in sarcoidosis, Expert Rev Respir Med 17(2) (2023) 119-130.
20. D.C. Patel, D. Valeyre, Advanced pulmonary sarcoidosis, Curr Opin Pulm Med 26(5) (2020) 574-581.
21. O.A. Shlobin, V. Kouranos, S.D. Barnett, E.H. Alhamad, D.A. Culver, J. Barney, F.C. Cordova, E.M. Carmona, M.B. Scholand, M. Wijsenbeek, S. Ganesh, E.E. Lower, P.J. Engel, J. Wort, L. Price, A.U. Wells, S.D. Nathan, R.P. Baughman, Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry, Eur Respir J 55(5) (2020).
22. O.N. Obi, S. Alqalyoobi, V. Maddipati, E.E. Lower, R.P. Baughman, High-Resolution CT Scan Fibrotic Patterns in Stage 4 Pulmonary Sarcoidosis: Impact on Pulmonary Function and Survival, Chest (2023).
23. M. Thillai, C.P. Atkins, A. Crawshaw, S.P. Hart, L.P. Ho, V. Kouranos, K. Patterson, N.J. Screaton, J. Whight, A.U. Wells, BTS Clinical Statement on pulmonary sarcoidosis, Thorax 76(1) (2021) 4-20.
24. J.P. Qiu, Bibliometrics (Second Edition). In: Cong Zou, Xiaoting Zhao, Liwei Qiao, editors. Science Press. Beijing: Academic;(2019).
25. Q.H. Pu, Q.J. Lyu, H.Y. Su, Bibliometric analysis of scientific publications in transplantation journals from Mainland China, Japan, South Korea and Taiwan between 2006 and 2015, BMJ Open 6(8) (2016) e011623.
26. C. Chen, Searching for intellectual turning points: progressive knowledge domain visualization, Proc Natl Acad Sci USA 101 Suppl 1(Suppl 1) (2004) 5303-10.
27. J. Li, C. Chen, CiteSpace:Text Mining and Visualization in Scientific Literature (Second Edition).In: Xue Xiaohong, editors. Capital University of Economics and Business Press. Beijing: Academic; (2016).
28. A.Z. Rasheed, M.L. Metersky, F. Ghazal, Mechanisms and management of cough in interstitial lung disease, Expert Rev Respir Med (2023) 1-14.
29. O.N. Obi, L.A. Saketkoo, A.M. Russell, R.P. Baughman, Sarcoidosis: Updates on therapeutic drug trials and novel treatment approaches, Front Med (Lausanne) 9 (2022) 991783.
30. K.C. Patterson, K. Hogarth, A.N. Husain, A.I. Sperling, T.B. Niewold, The clinical and immunologic features of pulmonary fibrosis in sarcoidosis, Transl Res 160(5) (2012) 321-31.
31. A. Remiker, K. Bolling, J. Verbsky, Common Variable Immunodeficiency, Med Clin North Am 108(1) (2024) 107-121.
32. D. Brady, L.P. Lavelle, S.H. McEvoy, D.J. Murphy, A. Gallagher, B. Gibney, M.W. Butler, F. Shortt, M. McMullan, A. Fabre, D.A. Lynch, S. Abbara, S.C. Donnelly, J.D. Dodd, Assessing fibrosis in pulmonary sarcoidosis: late-enhanced MRI compared to anatomic HRCT imaging, Qjm 109(4) (2016) 257-64.
33. G. Raghu, H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, T.V. Colby, J.F. Cordier, K.R. Flaherty, J.A. Lasky, D.A. Lynch, J.H. Ryu, J.J. Swigris, A.U. Wells, J. Ancochea, D. Bouros, C. Carvalho, U. Costabel, M. Ebina, D.M. Hansell, T. Johkoh, D.S. Kim, T.E. King, Jr., Y. Kondoh, J. Myers, N.L. Müller, A.G. Nicholson, L. Richeldi, M. Selman, R.F. Dudden, B.S. Griss, S.L. Protzko, H.J. Schünemann, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management, Am J Respir Crit Care Med 183(6) (2011) 788-824.
34. G. Raghu, M. Remy-Jardin, J.L. Myers, L. Richeldi, C.J. Ryerson, D.J. Lederer, J. Behr, V. Cottin, S.K. Danoff, F. Morell, K.R. Flaherty, A. Wells, F.J. Martinez, A. Azuma, T.J. Bice, D. Bouros, K.K. Brown, H.R. Collard, A. Duggal, L. Galvin, Y. Inoue, R.G. Jenkins, T. Johkoh, E.A. Kazerooni, M. Kitaichi, S.L. Knight, G. Mansour, A.G. Nicholson, S.N.J. Pipavath, I. Buendía-Roldán, M. Selman, W.D. Travis, S. Walsh, K.C. Wilson, Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, Am J Respir Crit Care Med 198(5) (2018) e44-e68.
35. W.D. Travis, U. Costabel, D.M. Hansell, T.E. King, Jr., D.A. Lynch, A.G. Nicholson, C.J. Ryerson, J.H. Ryu, M. Selman, A.U. Wells, J. Behr, D. Bouros, K.K. Brown, T.V. Colby, H.R. Collard, C.R. Cordeiro, V. Cottin, B. Crestani, M. Drent, R.F. Dudden, J. Egan, K. Flaherty, C. Hogaboam, Y. Inoue, T. Johkoh, D.S. Kim, M. Kitaichi, J. Loyd, F.J. Martinez, J. Myers, S. Protzko, G. Raghu, L. Richeldi, N. Sverzellati, J. Swigris, D. Valeyre, An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, Am J Respir Crit Care Med 188(6) (2013) 733-48.
36. S.L. Walsh, A.U. Wells, N. Sverzellati, G.J. Keir, L. Calandriello, K.M. Antoniou, S.J. Copley, A. Devaraj, T.M. Maher, E. Renzoni, A.G. Nicholson, D.M. Hansell, An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study, Lancet Respir Med 2(2) (2014) 123-30.
37. K.R. Flaherty, A.U. Wells, V. Cottin, A. Devaraj, S.L.F. Walsh, Y. Inoue, L. Richeldi, M. Kolb, K. Tetzlaff, S. Stowasser, C. Coeck, E. Clerisme-Beaty, B. Rosenstock, M. Quaresma, T. Haeufel, R.G. Goeldner, R. Schlenker-Herceg, K.K. Brown, Nintedanib in Progressive Fibrosing Interstitial Lung Diseases, N Engl J Med 381(18) (2019) 1718-1727.
38. H. Nunes, M. Humbert, F. Capron, M. Brauner, O. Sitbon, J.P. Battesti, G. Simonneau, D. Valeyre, Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis, Thorax 61(1) (2006) 68-74.
39. D. Valeyre, A. Prasse, H. Nunes, Y. Uzunhan, P.Y. Brillet, J. Müller-Quernheim, Sarcoidosis, Lancet 383(9923) (2014) 1155-67.
40. P. Spagnolo, G. Rossi, R. Trisolini, N. Sverzellati, R.P. Baughman, A.U. Wells, Pulmonary sarcoidosis, Lancet Respir Med 6(5) (2018) 389-402.
41. G. Kirkil, E.E. Lower, R.P. Baughman, Predictors of Mortality in Pulmonary Sarcoidosis, Chest 153(1) (2018) 105-113.
42. Q. Dong, Q. Liang, Y. Chen, J. Li, L. Lu, X. Huang, Q. Zhou, Bibliometric and Visual Analysis of Vascular Calcification Research, Front Pharmacol 12 (2021) 690392.
43. O. Distler, K.B. Highland, M. Gahlemann, A. Azuma, A. Fischer, M.D. Mayes, G. Raghu, W. Sauter, M. Girard, M. Alves, E. Clerisme-Beaty, S. Stowasser, K. Tetzlaff, M. Kuwana, T.M. Maher, Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease, N Engl J Med 380(26) (2019) 2518-2528.
44. K.C. Meyer, G. Raghu, R.P. Baughman, K.K. Brown, U. Costabel, R.M. du Bois, M. Drent, P.L. Haslam, D.S. Kim, S. Nagai, P. Rottoli, C. Saltini, M. Selman, C. Strange, B. Wood, An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease, Am J Respir Crit Care Med 185(9) (2012) 1004-14.
45. R. Trisolini, R.P. Baughman, P. Spagnolo, D.A. Culver, Endobronchial ultrasound-guided transbronchial needle aspiration in sarcoidosis: Beyond the diagnostic yield, Respirology 24(6) (2019) 531-542.
46. R.P. Baughman, E.E. Lower, Medical therapy of sarcoidosis, Semin Respir Crit Care Med 35(3) (2014) 391-406.
47. L.A. Saketkoo, R.P. Baughman, Biologic therapies in the treatment of sarcoidosis, Expert Rev Clin Immunol 12(8) (2016) 817-25.
48. R.P. Baughman, O.A. Shlobin, R. Gupta, P.J. Engel, J.I. Stewart, E.E. Lower, F.F. Rahaghi, J. Zeigler, S.D. Nathan, Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial, Chest 161(2) (2022) 448-457.
49. R.P. Baughman, M.A. Judson, D.A. Culver, S.S. Birring, J. Parambil, J. Zeigler, E.E. Lower, Roflumilast (Daliresp®) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial, Sarcoidosis Vasc Diffuse Lung Dis 38(3) (2021) e2021035.
50. A. Prasse, H. Binder, J.C. Schupp, G. Kayser, E. Bargagli, B. Jaeger, M. Hess, S. Rittinghausen, L. Vuga, H. Lynn, S. Violette, B. Jung, K. Quast, B. Vanaudenaerde, Y. Xu, J.M. Hohlfeld, N. Krug, J.D. Herazo-Maya, P. Rottoli, W.A. Wuyts, N. Kaminski, BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis, Am J Respir Crit Care Med 199(5) (2019) 622-630.
51. L. Bergantini, M. d'Alessandro, P. Cameli, A. Perrone, B. Cekorja, B. Boncompagni, M.A. Mazzei, P. Sestini, E. Bargagli, Integrated approach to bronchoalveolar lavage cytology to distinguish interstitial lung diseases, Eur J Intern Med 89 (2021) 76-80.
52. C. Landi, E. Bargagli, A. Carleo, L. Bianchi, A. Gagliardi, A. Prasse, M.G. Perari, R.M. Refini, L. Bini, P. Rottoli, A system biology study of BALF from patients affected by idiopathic pulmonary fibrosis (IPF) and healthy controls, Proteomics Clin Appl 8(11-12) (2014) 932-50.
53. E. Bargagli, M. Margollicci, A. Luddi, N. Nikiforakis, M.G. Perari, S. Grosso, A. Perrone, P. Rottoli, Chitotriosidase activity in patients with interstitial lung diseases, Respir Med 101(10) (2007) 2176-81.
54. M. d'Alessandro, L. Bergantini, P. Cameli, L. Vietri, N. Lanzarone, V. Alonzi, M. Pieroni, M.R. R, P. Sestini, F. Bonella, E. Bargagli, Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review, Biomark Med 14(8) (2020) 665-674.
55. P. Cameli, C. Caffarelli, R.M. Refini, L. Bergantini, M. d'Alessandro, M. Armati, M.D. Tomai Pitinca, P. Sestini, S. Gonnelli, E. Bargagli, Hypercalciuria in Sarcoidosis: A Specific Biomarker With Clinical Utility, Front Med (Lausanne) 7 (2020) 568020.
56. L. Vietri, M. d'Alessandro, L. Bergantini, A. Carleo, P. Cameli, M.A. Mazzei, P. Sestini, E. Bargagli, Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis, Intern Med J 50(12) (2020) 1571-1574.
57. M. d'Alessandro, E. De Vita, L. Bergantini, M.A. Mazzei, S. di Valvasone, M. Bonizzoli, A. Peris, P. Sestini, E. Bargagli, D. Bennett, Galactin-1, 3 and 9: Potential biomarkers in idiopathic pulmonary fibrosis and other interstitial lung diseases, Respir Physiol Neurobiol 282 (2020) 103546.
58. M. D'Alessandro, L. Bergantini, A. Carleo, P. Cameli, A. Perrone, A. Fossi, P. Sestini, E. Bargagli, Neutrophil-to-lymphocyte ratio in bronchoalveolar lavage from IPF patients: a novel prognostic biomarker?, Minerva Med 113(3) (2022) 526-531.
59. P. Cameli, E. Barbagli, P. Rottoli, Exhaled nitric oxide is not increased in pulmonary sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis 33(1) (2016) 39-40.
60. L. Bergantini, M. d'Alessandro, L. Vietri, G.D. Rana, P. Cameli, S. Acerra, P. Sestini, E. Bargagli, Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases, Immunol Res 68(6) (2020) 414-421.
61. P. Rottoli, E. Bargagli, C. Landi, B. Magi, Proteomic analysis in interstitial lung diseases: a review, Curr Opin Pulm Med 15(5) (2009) 470-8.
62. E. Shaba, C. Landi, A. Carleo, L. Vantaggiato, E. Paccagnini, M. Gentile, L. Bianchi, P. Lupetti, E. Bargagli, A. Prasse, L. Bini, Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways, Int J Mol Sci 22(11) (2021).
63. C. Landi, L. Bergantini, P. Cameli, M. d'Alessandro, A. Carleo, E. Shaba, P. Rottoli, L. Bini, E. Bargagli, Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy, Sci Rep 10(1) (2020) 9378.
64. T.E. King, Jr., Clinical advances in the diagnosis and therapy of the interstitial lung diseases, Am J Respir Crit Care Med 172(3) (2005) 268-79.
65. V. Cottin, N.A. Hirani, D.L. Hotchkin, A.M. Nambiar, T. Ogura, M. Otaola, D. Skowasch, J.S. Park, H.K. Poonyagariyagorn, W. Wuyts, A.U. Wells, Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases, Eur Respir Rev 27(150) (2018).
66. D.V. Pechkovsky, A. Prasse, F. Kollert, K.M. Engel, J. Dentler, W. Luttmann, K. Friedrich, J. Müller-Quernheim, G. Zissel, Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction, Clin Immunol 137(1) (2010) 89-101.
67. J.C. Schupp, H. Binder, B. Jäger, G. Cillis, G. Zissel, J. Müller-Quernheim, A. Prasse, Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis, PLoS One 10(1) (2015) e0116775.
68. I. Kotsianidis, E. Nakou, I. Bouchliou, A. Tzouvelekis, E. Spanoudakis, P. Steiropoulos, I. Sotiriou, V. Aidinis, D. Margaritis, C. Tsatalas, D. Bouros, Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis, Am J Respir Crit Care Med 179(12) (2009) 1121-30.
69. R. Malaviya, J.D. Laskin, D.L. Laskin, Anti-TNFα therapy in inflammatory lung diseases, Pharmacol Ther 180 (2017) 90-98.
70. H. Nunes, P.Y. Brillet, D. Valeyre, M.W. Brauner, A.U. Wells, Imaging in sarcoidosis, Semin Respir Crit Care Med 28(1) (2007) 102-20.
71. M.A. Judson, The Clinical Features of Sarcoidosis: A Comprehensive Review, Clin Rev Allergy Immunol 49(1) (2015) 63-78.
72. M. Silva, H. Nunes, D. Valeyre, N. Sverzellati, Imaging of Sarcoidosis, Clin Rev Allergy Immunol 49(1) (2015) 45-53.
73. H. Nunes, Y. Uzunhan, T. Gille, C. Lamberto, D. Valeyre, P.Y. Brillet, Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function, Eur Respir J 40(3) (2012) 750-65.
74. B. Duchemann, I. Annesi-Maesano, C. Jacobe de Naurois, S. Sanyal, P.Y. Brillet, M. Brauner, M. Kambouchner, S. Huynh, J.M. Naccache, R. Borie, J. Piquet, A. Mekinian, J. Virally, Y. Uzunhan, J. Cadranel, B. Crestani, O. Fain, F. Lhote, R. Dhote, N. Saidenberg-Kermanac'h, P.A. Rosental, D. Valeyre, H. Nunes, Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris, Eur Respir J 50(2) (2017).
75. Y. Jamilloux, D. Maucort-Boulch, S. Kerever, M. Gerfaud-Valentin, C. Broussolle, M. Eb, D. Valeyre, P. Seve, Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis, Eur Respir J 48(6) (2016) 1700-1709.
76. R. Lhote, I. Annesi-Maesano, H. Nunes, D. Launay, R. Borie, K. Sacré, N. Schleinitz, M. Hamidou, M. Mahevas, H. Devilliers, P. Bonniaud, F. Lhote, J. Haroche, P. Rufat, Z. Amoura, D. Valeyre, F. Cohen Aubart, Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort, Eur Respir J 57(4) (2021).
77. J. Le Pavec, D. Valeyre, P. Gazengel, A.M. Holm, H.H. Schultz, M. Perch, A. Le Borgne, M. Reynaud-Gaubert, C. Knoop, L. Godinas, S. Hirschi, V. Bunel, R. Laporta, S. Harari, E. Blanchard, J.M. Magnusson, A. Tissot, J.F. Mornex, C. Picard, L. Savale, J.F. Bernaudin, P.Y. Brillet, H. Nunes, M. Humbert, E. Fadel, J. Gottlieb, Lung transplantation for sarcoidosis: outcome and prognostic factors, Eur Respir J 58(2) (2021).
78. M. Mao , B. Guo, Q. Han. Interpretation of " Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline (2022 Edition)”: Identification and treatment of progressive pulmonary fibrosis. Inter J Respir Mede 43(11) (2023) 1245-1250.
79. M. Wijsenbeek, V. Cottin, Spectrum of Fibrotic Lung Diseases, N Engl J Med 383(10) (2020) 958-968.
80. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001, Am J Respir Crit Care Med 165(2) (2002) 277-304.
81. R. Sharif, Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines, Am J Manag Care 23(11 Suppl) (2017) S176-s182.
82. A. Caminati, C. Lonati, R. Cassandro, D. Elia, G. Pelosi, O. Torre, M. Zompatori, E. Uslenghi, S. Harari, Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue, Eur Respir Rev 28(153) (2019). 
83. F. Zhang, X. Dou, H. Zhang, Interpretation of " Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline (2022 Edition)”: Diagnosis and treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 43(11) (2023) 1251-1257.
84. D. Poch, J. Mandel, Pulmonary Hypertension, Ann Intern Med 174(4) (2021) Itc49-itc64.
85. H. Duong, C.A. Bonham, Sarcoidosis-associated Pulmonary Hypertension: Pathophysiology, Diagnosis, and Treatment, Clin Pulm Med 25(2) (2018) 52-60.
86. S. Li, H. Huang, Z. Xu, Recent development of fibrotic pulmonary sarcoidosis. Chin J Tuber and Respir Dis 41(11) (2018) 3.
87. A.F. Shorr, D.L. Helman, D.B. Davies, S.D. Nathan, Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics, Eur Respir J 25(5) (2005) 783-8.
88. A.F. Shorr, D.B. Davies, S.D. Nathan, Predicting mortality in patients with sarcoidosis awaiting lung transplantation, Chest 124(3) (2003) 922-8.
89. S.A. Christenson, B.M. Smith, M. Bafadhel, N. Putcha, Chronic obstructive pulmonary disease, Lancet 399(10342) (2022) 2227-2242.
90. M. Easter, S. Bollenbecker, J.W. Barnes, S. Krick, Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease, Int J Mol Sci 21(18) (2020).
91. M. Selman, F.J. Martinez, A. Pardo, Why Does an Aging Smoker's Lung Develop Idiopathic Pulmonary Fibrosis and Not Chronic Obstructive Pulmonary Disease?, Am J Respir Crit Care Med 199(3) (2019) 279-285.
92. Q.Lu, S. Han, X. Liu, Research progress in pathogenesis and influencing factors of fibrotic pulmonary sarcoidosis. J Jilin Univ: Medical Edition 49(2023) 1099-1106.
93. A. Sakula, BRONCHIAL CARCINOMA AND SARCOIDOSIS, Br J Cancer 17(2) (1963) 206-12.
94. I. Le Jeune, J. Gribbin, J. West, C. Smith, P. Cullinan, R. Hubbard, The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK, Respir Med 101(12) (2007) 2534-40.
95. K.C. Meyer, G. Raghu, Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful?, Eur Respir J 38(4) (2011) 761-9.
96. N. Hiwatari, S. Shimura, T. Takishima, K. Shirato, Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients, Tohoku J Exp Med 174(4) (1994) 379-86.
97. K. Xie, C. Wu, Changes in the role of pathology in the diagnosis and differential diagnosis of idiopathic pulmonary fibrosis. Chin J Path 2023, 52(6) (2023) 552-557.
98. N. Przysucha, K. Górska, R. Krenke, Chitinases and Chitinase-Like Proteins in Obstructive Lung Diseases - Current Concepts and Potential Applications, Int J Chron Obstruct Pulmon Dis 15 (2020) 885-899.
99. C.N. Rathcke, H. Vestergaard, YKL-40--an emerging biomarker in cardiovascular disease and diabetes, Cardiovasc Diabetol 8 (2009) 61.
100. C.G. Lee, C.A. Da Silva, C.S. Dela Cruz, F. Ahangari, B. Ma, M.J. Kang, C.H. He, S. Takyar, J.A. Elias, Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury, Annu Rev Physiol 73 (2011) 479-501.
101. X. Muñoz, M. Sánchez-Ortiz, F. Torres, A. Villar, F. Morell, M.J. Cruz, Diagnostic yield of specific inhalation challenge in hypersensitivity pneumonitis, Eur Respir J 44(6) (2014) 1658-65.
102. K. Otsuka, H. Matsumoto, A. Niimi, S. Muro, I. Ito, T. Takeda, K. Terada, M. Yamaguchi, H. Matsuoka, M. Jinnai, T. Oguma, H. Nakaji, H. Inoue, T. Tajiri, T. Iwata, K. Chin, M. Mishima, Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease, Respiration 83(6) (2012) 507-19.
103. I.J. Yeo, C.K. Lee, S.B. Han, J. Yun, J.T. Hong, Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases, Pharmacol Ther 203 (2019) 107394.
104. J.L. Gomez, X. Yan, C.T. Holm, N. Grant, Q. Liu, L. Cohn, V. Nezgovorova, D.A. Meyers, E.R. Bleecker, G.M. Crisafi, N.N. Jarjour, L. Rogers, J. Reibman, G.L. Chupp, Characterisation of asthma subgroups associated with circulating YKL-40 levels, Eur Respir J 50(4) (2017).
105. I. Bara, A. Ozier, P.O. Girodet, G. Carvalho, J. Cattiaux, H. Begueret, M. Thumerel, O. Ousova, R. Kolbeck, A.J. Coyle, J. Woods, J.M. Tunon de Lara, R. Marthan, P. Berger, Role of YKL-40 in bronchial smooth muscle remodeling in asthma, Am J Respir Crit Care Med 185(7) (2012) 715-22.
106. K. Furuhashi, T. Suda, Y. Nakamura, N. Inui, D. Hashimoto, S. Miwa, H. Hayakawa, H. Kusagaya, Y. Nakano, H. Nakamura, K. Chida, Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis, Respir Med 104(8) (2010) 1204-10.
107. G. Chen, T. Yang, Q. Gu, X.H. Ni, Z.H. Zhao, J. Ye, X.M. Meng, Z.H. Liu, J.G. He, C.M. Xiong, Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension, Respirology 19(4) (2014) 608-15.
108. X. Long, X. He, S. Ohshimo, M. Griese, R. Sarria, J. Guzman, U. Costabel, F. Bonella, Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis, Eur Respir J 49(2) (2017). 
109. Q. Zhang, H. Huang, Z. Xu, Progression in diagnose and treatment of pulmonary sarcoidosis. J Clin Intern Med 37(10) (2020) 5.
110. J. Behr, A. Prasse, M. Kreuter, J. Johow, K.F. Rabe, F. Bonella, R. Bonnet, C. Grohe, M. Held, H. Wilkens, P. Hammerl, D. Koschel, S. Blaas, H. Wirtz, J.H. Ficker, W. Neumeister, N. Schönfeld, M. Claussen, N. Kneidinger, M. Frankenberger, S. Hummler, N. Kahn, S. Tello, J. Freise, T. Welte, P. Neuser, A. Günther, Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial, Lancet Respir Med 9(5) (2021) 476-486.
111. T.M. Maher, T.J. Corte, A. Fischer, M. Kreuter, D.J. Lederer, M. Molina-Molina, J. Axmann, K.U. Kirchgaessler, K. Samara, F. Gilberg, V. Cottin, Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial, Lancet Respir Med 8(2) (2020) 147-157.
112. R. Kandolin, J. Lehtonen, J. Airaksinen, T. Vihinen, H. Miettinen, K. Ylitalo, K. Kaikkonen, S. Tuohinen, P. Haataja, T. Kerola, J. Kokkonen, M. Pelkonen, P. Pietilä-Effati, S. Utrianen, M. Kupari, Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study, Circulation 131(7) (2015) 624-32.
113. J. Lehtonen, V. Uusitalo, P. Pöyhönen, M.I. Mäyränpää, M. Kupari, Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis, Eur Heart J 44(17) (2023) 1495-1510.
114. R.P. Baughman, D. Valeyre, P. Korsten, A.G. Mathioudakis, W.A. Wuyts, A. Wells, P. Rottoli, H. Nunes, E.E. Lower, M.A. Judson, D. Israel-Biet, J.C. Grutters, M. Drent, D.A. Culver, F. Bonella, K. Antoniou, F. Martone, B. Quadder, G. Spitzer, B. Nagavci, T. Tonia, D. Rigau, D.R. Ouellette, ERS clinical practice guidelines on treatment of sarcoidosis, Eur Respir J 58(6) (2021).
115. L. Biener, J. Kruse, I. Tuleta, C. Pizarro, M. Kreuter, S.S. Birring, G. Nickenig, D. Skowasch, Association of proangiogenic and profibrotic serum markers with lung function and quality of life in sarcoidosis, PLoS One 16(2) (2021) e0247197. 
Acknowledgements
The authors acknowledge Beijing University of Chinese Medicine for their support of this work.